Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...
Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...
An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...
3d
Pharmaceutical Technology on MSNOno earmarks $940m to gain rare blood cancer therapy from IonisJapan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis ...
Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.
Among phlebotomy-dependent patients with polycythemia vera, the addition of rusfertide to standard-of-care treatment resulted ...
Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV). The 3-part, randomized, ...
About Polycythemia Vera (PV) PV is a rare and potentially life-threatening hematologic disease characterized by the overproduction of red blood cells, which significantly increases the risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results